Pioglitazone is a new orally active thiazolidinedione (TZD) launched in the US for the treatment of non-insulin dependent diabetes mellitus (NIDDM).
Soluble in water (<1 mg/ml at 25C), DMF, methanol, ethanol (4 mg/ml at 25C), and DMSO (79 mg/ml at 25C).
392.9 Grams (g)
112529-15-4
Powder
Other
Pioglitazone API
Pioglitazone API
Medicine Grade
Other
29341000
C19H21ClN2O3S
Other
99%
193-194C
Pioglitazone API Trade Information
Mumbai
Western Union Paypal Cash in Advance (CID) Cash Advance (CA)
5000 Kilograms Per Week
15 Days
As Per Requirement.
Western Europe Australia North America Eastern Europe Central America Middle East South America Asia Africa
All India
Product Description
PioglitazoneÃÂÃÂ is an orally-activeÃÂÃÂ thiazolidinedioneÃÂÃÂ with antidiabetic properties and potential antineoplastic activity.ÃÂÃÂ PioglitazoneÃÂÃÂ activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.